α-glucosidase x GANC x MGAM

This study aimed to study the pharmacodynamic characteristics of a single fasting oral administration of voglibose tablets (0.2 mg) produced by Beijing Xinghao Pharmaceutical Co., Ltd.; using voglibose tablets (Bexin®, 0.2 mg) produced by Tianjin Takeda Pharmaceutical Co., Ltd. as the reference preparation, to compare the △CSG,max and △AUEC0-2 h of blood glucose after oral administration of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Primary objective: To compare the pharmacodynamic parameters of voglibose tablets (specification: 0.3 mg) produced by Shanghai Modern Pharmaceutical Co., Ltd. and voglibose tablets (trade name: Beixin®, specification: 0.3 mg) certified by Teva Takeda Yakuhin Ltd. using a randomized, open, single-dose, two-preparation, two-sequence, four-period, completely repeated crossover design, and to evaluate the bioequivalence of the test preparation and the reference preparation under fasting conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.